USPTO Art Unit 1634 Prosecution Statistics

Art Unit Information

Art Unit: 1634
Group: 1630
Tech Center: 1600
Total Cases: 16,308
Last Active: July 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19270414USE OF G007-LK IN PROMOTING OSTEOGENIC DIFFERENTIATION OF DENTAL MESENCHYMAL STEM CELLS AND BONE TISSUE REGENERATIONJuly 2025November 2025Allow401NoNo
19209435COMPOSITIONS AND METHODS FOR TREATMENTMay 2025October 2025Allow511YesNo
19180809REGULATION OF ARTIFICIAL MIRNAS BY ENDOGENOUS TISSUE-SPECIFIC MIRNAS AND METHODS OF USING THE SAMEApril 2025February 2026Abandon1010NoNo
19083713METHOD FOR PREPARING HEMOGENIC ENDOTHELIUM CELL AND METHOD FOR PREPARING HEMATOPOIETIC STEM CELL OR HEMATOPOIETIC STEM AND PROGENITOR CELLMarch 2025December 2025Allow910NoNo
19050950COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDFebruary 2025December 2025Allow1110NoNo
18988990ULTRA-HIGH-CELL-DENSITY MULTICELLULAR TISSUE LIFTING BIOPRINTING DEVICE ASSISTED BY OBLIQUE INCIDENT BULK WAVE AND PRINTING METHOD THEREFORDecember 2024April 2025Allow400NoNo
18983137METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPYDecember 2024March 2025Allow310NoNo
18873580STAGED CULTURE METHOD FOR IN-VITRO EXPANSION OF HUMAN CYTOKINE-INDUCED KILLER (CIK) AND USE THEREOFDecember 2024August 2025Allow810YesNo
18948694RECOMBINANT AAV VECTORS FOR TREATING GLUTARIC ACIDURIA TYPE INovember 2024August 2025Allow911YesNo
18948625BACULOVIRUS VECTOR AND USE THEREOF IN PREPARATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS (rAAV) IN INSECT CELLNovember 2024December 2025Allow1321YesNo
18936497METHODS USING SURFACE-EXPRESSIBLE ACTIVATABLE EPITOPES TO LOCALIZE AND/OR TREAT DISEASED CELLSNovember 2024October 2025Abandon1110NoNo
18919051ANTIGEN BINDING POLYPEPTIDESOctober 2024May 2025Abandon601YesNo
18919103COMPOSITIONS FOR TREATING CANCEROctober 2024July 2025Allow921YesNo
18913027COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSOctober 2024May 2025Allow710NoNo
18849551MODIFIED VECTOR, CONSTRUCTION METHOD, AND APPLICATION OF MODIFIED AAV-8 SEROTYPE FOR GENE TARGETING AND EXPRESSIONSeptember 2024February 2026Allow1721NoNo
18891235COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024January 2026Allow1530NoNo
18885902COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINSSeptember 2024May 2025Allow810NoNo
18827471GENE THERAPY FOR SPINAL MUSCULAR ATROPHYSeptember 2024July 2025Allow1111NoNo
18822374APPLICATION OF NANO LAYERED DOUBLE HYDROXIDE IN CARTILAGE REGENERATION AND PREPARATION THEREOFSeptember 2024April 2025Allow811NoNo
18817528CD34 STEM CELL MIMICSAugust 2024June 2025Allow1011YesNo
18841165MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTIONAugust 2024August 2025Allow1211NoNo
18784317COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJuly 2024February 2025Allow610NoNo
18738959COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINSJune 2024January 2025Allow710YesNo
18731209REAGENTS, REAGENT KITS, AND CULTURE MEDIA FOR ACTIVATING AND EXPANDING IMMUNE CELLS AND USES THEREOFMay 2024May 2025Allow1221YesNo
18646835ADENO-ASSOCIATED VIRUS CAPSIDApril 2024November 2025Allow1830YesNo
18618894PLACENTAL MESENCHYMAL STEM CELLS, METHODS OF PRODUCTION, AND PLACENTAL MESENCHYMAL STEM CELL BASED THERAPEUTICSMarch 2024February 2026Abandon2311NoNo
18612729Materials and Methods for Treatment of HemoglobinopathiesMarch 2024August 2025Abandon1621NoNo
18601387SYSTEM AND METHOD FOR CONVERTING ADIPOSE DERIVED MESENCHYMAL STEMS CELLS TO HEMATOPOIETIC STEM/PROGENITOR CELLS AND DIFFERENTIATING INTO BLOOD CELLS AND APPLICATIONS OF SAMEMarch 2024March 2026Abandon2431YesNo
18593476BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTIONMarch 2024March 2026Abandon2430YesNo
18435722PRESERVATION OF PANCREATIC ISLET GRAFTS IN THE EXTRAHEPATIC SPACEFebruary 2024August 2025Allow1930YesNo
18431132Egg Preparation in an Intelligent Automated In Vitro Fertilization and Intracytoplasmic Sperm Injection PlatformFebruary 2024February 2025Allow1311YesNo
18427711NON-TRANSGENE TRANSFECTION FOR THERAPEUTIC PURPOSESJanuary 2024June 2025Allow1730YesNo
18419406METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTSJanuary 2024July 2024Allow510YesNo
18414374CHEMOPREDICTIVE ASSAY FOR RECURRENT CHEMOTHERAPYJanuary 2024March 2025Abandon1410NoNo
18412312SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROWJanuary 2024March 2026Allow2610NoNo
18405995CRISPR/CAS9-BASED REPRESSORS FOR SILENCING GENE TARGETS IN VIVO AND METHODS OF USEJanuary 2024May 2025Allow1720YesNo
18567880ISOLATED CELL MEMBRANE POTENTIAL DETECTION SYSTEM AND METHOD BASED ON MULTI-SPECTRAL MULTI-PARAMETER PHOTOSTIMULATIONDecember 2023November 2024Allow1110YesNo
18524212PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED CD163 GENESNovember 2023October 2024Allow1120YesNo
18513347RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOFNovember 2023November 2025Allow2411YesNo
18505026PERSONALIZED METHODS FOR DETECTING CIRCULATING TUMOR DNANovember 2023August 2024Allow930YesNo
18497415SPATIAL TRANSCRIPTOMICS FOR ANTIGEN-RECEPTORSOctober 2023July 2024Allow920NoNo
18490030PAPN MUTANT AND COMPOSITION FOR SITE-DIRECTED MODIFICATION OF PAPN GENE AND APPLICATION THEREOFOctober 2023January 2025Allow1521NoNo
18485458ACELLULAR COMPOSITIONS AND METHODSOctober 2023March 2025Abandon1710NoNo
18483878METHODS AND COMPOSITIONS FOR EVALUATING GENETIC MARKERSOctober 2023July 2025Abandon2100NoNo
18481950DETECTION AND DIGITAL QUANTITATION OF MULTIPLE TARGETSOctober 2023April 2024Allow610NoNo
18375868LYMPHOCYTE TARGETED LENTIVIRAL VECTORSOctober 2023April 2024Allow720YesNo
18474506Cross-Species Compatible Adeno-Associated Virus Compositions and Methods of Use ThereofSeptember 2023July 2024Allow910YesNo
18371858METHODS TO PREVENT TERATOGENICITY OF IMID LIKE MOLECULES AND IMID BASED DEGRADERS/PROTACSSeptember 2023July 2025Abandon2211NoNo
18471447CHEMICAL COMPOSITIONS AND METHODS OF USING SAMESeptember 2023April 2024Allow710YesNo
18370826PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINSSeptember 2023May 2024Abandon811NoNo
18370000USING DREADD FOR NEURONAL MODULATION IN TREATING NEURONAL DISEASESSeptember 2023August 2025Abandon2301NoNo
18470189SMALL TYPE II-D CAS PROTEINS AND METHODS OF USE THEREOFSeptember 2023September 2024Allow1221YesNo
18279201LYMPHOCYTE TARGETED LENTIVIRAL VECTORSAugust 2023February 2026Abandon3011NoNo
18275591TARGETED EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTICSAugust 2023October 2024Allow1510NoNo
18361305ANTI-FIBROTIC COMPOSITIONS COMPRISING FENDRR OR FRAGMENTS OR VARIANTS THEREOF AND METHODS OF PRODUCTION AND USE THEREOFJuly 2023November 2025Allow2820YesNo
18359013HIGH-TRANSDUCING HSV VECTORSJuly 2023December 2024Allow1610NoNo
18351800ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLSJuly 2023November 2024Allow1720YesNo
18351674ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLSJuly 2023November 2024Allow1640YesNo
18351689ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLSJuly 2023November 2024Allow1620YesNo
18351651PLASMID TARGET, PRIMER PROBE, KIT AND METHOD FOR DETECTING RESIDUAL HOST DNA IN CELLULAR OR VIRAL FORMULATIONJuly 2023September 2024Abandon1411YesNo
18221026SYSTEMS AND METHODS FOR PRODUCING INJECTABLE ENHANCED STEM CELL EXOSOMES, IMPROVED EXOSOMES AND METHODS OF USEJuly 2023March 2025Allow2041YesNo
18351345METHOD FOR FORMING A POROUS CELL SUBSTRATEJuly 2023October 2024Allow1521YesNo
18217310PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINSJune 2023March 2024Abandon910NoNo
18344732HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIESJune 2023April 2025Allow2111YesNo
18341701MESENCHYMAL STEM CELLS FOR TREATMENT OF SKIN DISORDERS AND SKIN PROBLEMSJune 2023August 2025Abandon2630NoNo
18259177Nanopatterned Films with Patterned Surface ChemistryJune 2023June 2024Allow1110YesNo
18340501METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING ANALYTES FROM GLIOBLASTOMA SAMPLESJune 2023June 2024Abandon1211NoNo
18336901METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTSJune 2023January 2024Allow710YesNo
18335598TRPC3 AS A THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASEJune 2023October 2025Abandon2811NoNo
18322531METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOFMay 2023January 2024Allow820NoNo
18320789NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUSMay 2023March 2026Allow3410NoNo
18199013NANOBARCODE FOR CONTROLLING CELL ADHESION AND DIFFERENTIATION OF STEM CELLS, PREPARATION METHOD THEREOF, AND METHOD OF CONTROLLING ADHESION AND DIFFERENTIATION OF STEM CELLS BY USING THE SAMEMay 2023February 2025Allow2110YesNo
18317841MICRONEEDLE DEVICES AND METHODS, AND SKIN CONDITION ASSAYSMay 2023September 2024Abandon1611NoNo
18316899VIRAL VECTORS FOR CANCER THERAPYMay 2023May 2025Allow2430YesNo
18315289SPATIAL TRANSCRIPTOMICS FOR ANTIGEN-RECEPTORSMay 2023October 2023Allow510NoNo
18141534MOLECULAR WIRES FOR DETECTING A BIOLOGICAL OR CHEMICAL ENTITY OR EVENTMay 2023December 2023Allow710NoNo
18306518THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCERApril 2023December 2023Abandon810NoNo
18138361TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASESApril 2023June 2025Abandon2511NoNo
18137110HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCIApril 2023March 2026Allow3510NoNo
18295483METHOD AND APPARATUS FOR MESENCHYMAL STEM CELLS PURIFICATIONApril 2023March 2026Abandon3501NoNo
18129357METHODS AND SYSTEMS FOR DETERMINING SPATIAL PATTERNS OF BIOLOGICAL TARGETS IN A SAMPLEMarch 2023September 2023Allow610NoNo
18192107MOLECULAR MARKER FOR GENETIC RESISTANCE OF CHICKEN TO INFECTION BY SUBGROUPS A AND K AVIAN LEUKOSIS VIRUS AND USE THEREOFMarch 2023July 2024Abandon1510YesNo
18188755MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCEMarch 2023January 2024Allow1011NoNo
18187578MOLECULE COUNTING OF METHYLATED CELL-FREE DNA FOR TREATMENT MONITORINGMarch 2023January 2024Allow1020YesNo
18185118GENERATING CAPTURE PROBES FOR SPATIAL ANALYSISMarch 2023October 2023Allow710NoNo
18184615METHOD AND APPARATUS FOR RAPID ANALYSIS OF A BIOLOGICAL SAMPLEMarch 2023February 2024Allow1110NoNo
18120059KIT, DEVICE, AND METHOD FOR DETECTING LUNG CANCERMarch 2023March 2024Allow1201YesNo
18179684CHEMICAL COMPOSITIONS AND METHODS OF USING SAMEMarch 2023September 2023Allow711NoNo
18179924AFFINITY REAGENTS HAVING ENHANCED BINDING AND DETECTION CHARACTERISTICSMarch 2023March 2024Allow1310NoNo
18179795SPATIAL ANALYSIS TO DETECT SEQUENCE VARIANTSMarch 2023December 2023Allow910YesNo
18179961FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOODMarch 2023October 2023Allow820NoNo
18179945FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOODMarch 2023November 2023Allow820NoNo
18116863METHODS FOR PRODUCING MATURE ADIPOCYTES AND METHODS OF USE THEREOFMarch 2023January 2026Allow3410YesNo
18023739DETECTION KIT FOR SALMONELLA TYPHI , PREPARATION METHOD AND APPLICATION THEREOFFebruary 2023July 2024Allow1611YesNo
18176360DETECTION AND TREATMENT OF AUTISM SPECTRUM DISORDERSFebruary 2023August 2024Abandon1810NoNo
18112116COMPOSITIONS AND METHODS FOR DETERMINING ENDOMETRIAL CANCER PROGNOSISFebruary 2023July 2024Abandon1601NoNo
18168517DIAGNOSIS OF SEPSISFebruary 2023August 2024Abandon1801NoNo
18108699FIBROUS BIRTH TISSUE COMPOSITION AND METHOD OF USEFebruary 2023April 2025Allow2611NoNo
18166447METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPYFebruary 2023November 2024Allow2230YesNo
18107000IN VIVO Method for Generating Diversity in a Protein ScaffoldFebruary 2023January 2026Allow3610YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1634.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
278
Examiner Affirmed
192
(69.1%)
Examiner Reversed
86
(30.9%)
Reversal Percentile
43.6%
Lower than average

What This Means

With a 30.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1773
Allowed After Appeal Filing
274
(15.5%)
Not Allowed After Appeal Filing
1499
(84.5%)
Filing Benefit Percentile
1.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1634 - Prosecution Statistics Summary

Executive Summary

Art Unit 1634 is part of Group 1630 in Technology Center 1600. This art unit has examined 16,308 patent applications in our dataset, with an overall allowance rate of 38.3%. Applications typically reach final disposition in approximately 37 months.

Comparative Analysis

Art Unit 1634's allowance rate of 38.3% places it in the 2% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1634 receive an average of 2.19 office actions before reaching final disposition (in the 72% percentile). The median prosecution time is 37 months (in the 21% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.